000 | 03360na a2200301 4500 | ||
---|---|---|---|
003 | H12O | ||
005 | 20210625062802.0 | ||
008 | 130622s2011 xxx||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_aCriado Carrasco, Gabriel _91880 _eInstituto de Investigación i+12 |
||
100 |
_aRey Cerros, Manuel José del _91881 _eInstituto de Investigación i+12 |
||
100 |
_aIzquierdo Alvárez, Elena _91882 _eInstituto de Investigación i+12 |
||
100 |
_91010 _aPablos Álvarez, José Luis _eReumatología |
||
100 |
_aUsátegui Corral, Alicia _91883 _eInstituto de Investigación i+12 |
||
245 | 0 | 0 |
_aSynovial fibroblast hyperplasia in rheumatoid arthritis: clinicopathologic correlations and partial reversal by anti-tumor necrosis factor therapy _h[artículo] |
260 |
_bArthritis and Rheumatism, _c2011 |
||
300 | _a63(9):2575-2583. | ||
500 | _aFormato Vancouver: Izquierdo E, Cañete JD, Celis R, Del Rey MJ, Usategui A, Marsal S, et al. Synovial fibroblast hyperplasia in rheumatoid arthritis: clinicopathologic correlations and partial reversal by anti-tumor necrosis factor therapy. Arthritis Rheum. 2011;63(9):2575-83. | ||
501 | _aPMID: 21547893 | ||
504 | _aContiene 36 referencias | ||
520 | _aSynovial fibroblast (SF) hyperplasia contributes to the pathogenesis of rheumatoid arthritis (RA), but quantitative information on this process is scarce. This study was undertaken to evaluate the fibroblast-specific marker Hsp47 as a quantitative marker for SFs and to analyze its clinicopathologic correlates and evolution after anti-tumor necrosis factor α (anti-TNFα) therapy. METHODS: Synovial biopsy samples were obtained from 48 patients with RA and 20 controls who were healthy or had osteoarthritis (OA). Twenty-five RA patients who had active disease at the time of biopsy underwent a second biopsy after anti-TNFα therapy. Immunolabeling for Hsp47, inflammatory cells, and vascular cell markers was performed. Hsp47-positive lining and sublining fractional areas were quantified, and their correlation with clinicopathologic variables was analyzed. RESULTS: In normal and diseased synovial tissue, Hsp47 was specifically and uniformly expressed by lining, sublining, and perivascular fibroblasts. Lining SF area was significantly increased in both RA and late OA tissue compared to normal tissue. Sublining SF area was increased in RA tissue but not in late OA tissue compared to normal tissue. Lining SF area was positively correlated with macrophage density, Disease Activity Score in 28 joints, and RA disease duration. In contrast, sublining SF area was negatively correlated with RA disease duration and activity. A significant reduction in lining SF area but not sublining SF area was observed after anti-TNFα therapy. CONCLUSION: Our findings indicate that Hsp47 is a reliable marker for quantifying SFs in human synovial tissue. Our data suggest that lining and sublining SFs undergo different dynamics during the course of the disease. Lining SF expansion parallels the activity and temporal progression of RA and can be partially reversed by anti-TNFα therapy. | ||
650 | _aAdult | ||
710 |
_9625 _aInstituto de Investigación imas12 |
||
710 |
_9123 _aServicio de Reumatología |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/5/pc5805.pdf _ySolicitar documento |
||
942 |
_n0 _2ddc _cART |
||
999 |
_c5805 _d5805 |